# EDGAR Filing Document

**Accession Number:** 0001745999
**File Stem:** 0000899243-23-010140
**Filing Date:** 2023-3
**Character Count:** 6731
**Document Hash:** fb1564b609a11a61880a46de5f208732
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000899243-23-010140.hdr.sgml**: 20230331

**ACCESSION NUMBER**: 0000899243-23-010140

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230330

**FILED AS OF DATE**: 20230331

**DATE AS OF CHANGE**: 20230331

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Bellon Christine
- **CENTRAL INDEX KEY:** 0001963878

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39208
- **FILM NUMBER:** 23789946

**MAIL ADDRESS:**
- **STREET 1:** BEAM THERAPEUTICS, INC.
- **STREET 2:** 238 MAIN STREET, 9TH FL.
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Beam Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001745999
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 26 LANDSDOWNE STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** 857-327-8775

**MAIL ADDRESS:**
- **STREET 1:** 26 LANDSDOWNE STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Bellon Christine<br><sub>(Last) (First) (Middle)</sub><br>C/O BEAM THERAPEUTICS INC.<br>238 MAIN STREET<br><sub>(Street)</sub><br>CAMBRIDGE, MA 02142<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-03-30 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Legal Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Beam Therapeutics Inc. [ BEAM ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-03-30 |  | M |  | 6272 | A | $7.22 | 64713 | D |  |
| Common Stock | 2023-03-30 |  | M |  | 2669 | A | $7.22 | 67382 | D |  |
| Common Stock | 2023-03-31 |  | A |  | 17500<sup>(1)</sup> | A | $0.00 | 84882 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $7.22 | 2023-03-30 |  | M |  |  | 6272 | <sup>(2)</sup> | 2029-05-16 | Common Stock | 6272 | $0.00 | 13674 | D |  |
| Stock Option (Right to Buy) | $7.22 | 2023-03-30 |  | M |  |  | 2669 | <sup>(3)</sup> | 2029-05-17 | Common Stock | 2669 | $0.00 | 16736 | D |  |

---

### Footnotes:

(1) Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM")  2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

(2) This stock option vests as to 25% on the first anniversary of the vesting commencement date, May 16, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested.

(3) This stock option vests as to 25% on the first anniversary of the vesting commencement date, May 17, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested.

**Signature:** By: /s/ Christine Bellon  
**Date:** 2023-03-31

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**